Skip to main content
. 2016 Jan 27;6:19772. doi: 10.1038/srep19772

Figure 3. Assessment of the ADCC bioassay using the NK cell line.

Figure 3

(a) The BT-474 as target cells were incubated overnight with NK92MI + CD16a as effector cells at various E:T ratios without (white bar) or with 10 μg/mL of Trastuzumab (black bar). (b,c) The three human breast cancer cell lines, expressing different HER2 levels, serving as target cells were incubated overnight with the NK92 + CD16a as effector cells, at an E:T ratio of 1:1, without (white bar) or with 10 μg/mL of Trastuzumab (black bar) or Bevacizumab (dot bar) using the flowcytometric assay (b) or calcein-release assay (c). The results of the analyses of dead cells (%) and ADCC (%) are presented as mean values ± SD of at least three experiments.